# CCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ccell

- Industry: Healthcare
- Headquarters: Suzhou, China
- Website: www.cancercell.com.cn
- Total disclosed funding: $1.4M
- Latest round: Angel (Jun 18, 2024)
- Investors on record: 1

## About

Based in Suzhou, China, and founded in 2014, CCell is a medical testing company specialising in the provision of technical services in animal histopathology testing. It has regional laboratories in Shanghai, Hangzhou and Nanjing. The company has applied for more than ten invention patents. The chief scientist, Shouli Wang, was a chief pathologist of Namsa China Laboratory. It established the Key Laboratory of Toxicological Patholog with Suzhou University in 2018. In June 2024, CCell closed angel funding from Yunsong Capital.

CCell develops products based on conventional histopathological technology, molecular pathology technology, and the German Eckhardt tissue sectioning technology platform. Its products include tissue fixative, staining solution, molecular pathology test kits, hard tissue sectioning consumables, IHC automatic staining system and intelligent diagnostic system. The company's products can serve GLP (Good Laboratory Practic) systemised CRO organisations and medical units. It also provides a range of animal histopathology services for life sciences, medical research, drug and medical device development.

The company generates revenue by providing tissue fixative, staining solution, molecular pathology test kits, hard tissue sectioning consumables and other products and integrated technical services for animal histopathological testing.

The company will set up a production laboratory in Anhui.

## Funding rounds

- Angel, Jun 18, 2024, $1.4M — Yunsong Capital

## Investors

- Yunsong Capital (https://capitalatlas.ai/funds/yunsong-capital) — Angel